Sun Pharma up 6% on USFDA nod for anti-cancer drug Gleevec

[capitalstars Equity tips]

Shares of Sun Pharmaceutical Industries surged more than 6 percent intraday Friday after its subsidiary has received approval from the US health regulator for anti-cancer drug. "The subsidiary today has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Gleevec, imatinib mesylate tablets 100mg and 400mg," says the country's largest drug maker in its filing.


Stock Trading Tips , Free Intraday Tips 

GET -  free intraday tips for tomorrow